ArticleFrontiers in medicine2026
The clinical utility of combining D-dimer with the C-reactive protein/albumin ratio for assessing treatment response in pediatric infectious mononucleosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluates the effectiveness of tracking D-dimer levels and the CRP/ALB ratio for objective quantification of therapeutic response and complication risk in children with infectious mononucleosis (IM). Methods: This study involved 171 hospitalized children diagnosed with IM, comprising 116 patients without complications and 55 with complications. Measurements of D-dimer, CRP, albumin, and atypical lymphocytes percentage (ALC) were taken within 24 h of admission and again on the fifth day of treatment to calculate the rate of change. Independent predictors were identified through logistic regression analysis, and the model's performance was validated using receiver operating characteristic (ROC) curves in both training and validation cohorts. Results: Although baseline markers were comparable between groups, post-treatment analysis revealed that the complications group exhibited persistent hypercoagulability and inflammation, as evidenced by elevated levels of D-dimer and CRP/ALB, along with a slower decline in atypical lymphocytes percentage (ALC) ( Conclusions: Short-term changes of routine markers, particularly D-dimer and CRP/ALB, in conjunction with fever duration, may facilitate the objective evaluation of therapeutic efficacy and assist in risk stratification for complications in pediatric IM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.